Objective：This study aims to investigate the safety and efficacy of transjugular intrahepatic portosystemic stent shunt (TIPS)combined with percutaneous transhepatic variceal embolization(PTVE)in the treatment of esophagogastric variceal bleeding in liver cirrhosis caused by autoimmune liver diseases(AILD).Methods：From August 2015 to September 2021，the clinical data of 23 patients(2 males and 21 females)with esophagogastric variceal bleeding in liver cirrhosis caused by AILD were retrospectively analyzed. All patients received TIPS and PTVE treatment after conservative and/or endoscopic treatment failed to control bleeding. The immediate bleeding control rate，rebleeding rate，rebleeding⁃free survival，overall survival and complications were evaluated. Results： Patients showed a high immediate bleeding control rate(100%). The 1⁃，2⁃，and 3⁃year rebleeding rate were 9.6%，17.1%，and 17.1%， respectively. The median rebleeding⁃free survival time was 455 days(range：70⁃1 308 days). The 1⁃，2⁃，3⁃year survival rate was 100%， 91.7%，and 91.7%，respectively. The median overall survival time was 611 days(range：85 ⁃ 1 308 days). The severe short ⁃ term complications included acute cardiac insufficiency(1 case)and intra ⁃abdominal hemorrhage(1 case). Long ⁃term complications were hepatic encephalopathy(4 cases)，with West Haven grade Ⅲ in 1 case and West Haven Grade Ⅱ in other 3 cases. Conclusion：TIPS combined with PTVE may be safe and effective in the management of esophagogastric variceal bleedingin liver cirrhosis caused by AILD.